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Peritoneal dialysis solutions reverse the hemodynamic effects of
nitric oxide synthesis inhibitors
RANDALL WHITE, DARREN BAREFIELD, SUNANDA RAM, and JACK WORK
Division of Nephrology and Hypertension, Department of Medicine, Louisiana State University Medical Center, Shreveport, Louisiana, USA
Peritoneal dialysis solutions reverse the hemodynamic effects of nitric
oxide synthesis inhibitors. Nitric oxide (NO) synthesis is inhibited by a
variety of L-arginine analogs including NGnitroLarginine methyl ester(L-NAME) and NG N°-dimethylarginine (ADMA). ADMA is present in
elevated concentrations in renal failure and potentially could alter micro-
circulatory hemodynamics during peritoneal dialysis (PD). This investiga-
tion utilized the techniques of intravital microscopy to quantitate the
mesenteric arteriolar hemodynamic effects of PD solutions during NO
synthesis inhibition. L-NAME (100 M) produced maximum arteriolar
vasoconstriction to 74% of baseline diameter (19.9 2.2 vs. 26.9 1.4
j.m, P < 0.001, N = 10) and ADMA (100 to 68% (20.5 2.5 vs. 30.1
2.0 .sm, P < 0.01, N = 6). L-NAME decreased red blood cell velocity
to 44% of baseline velocity (3.8 0.8 vs. 8.5 1.1 mm/second, P < 0.00 1)
and ADMA to 52% (5.1 1.1 vs. 9.8 0.9 mm/second, P < 0.01, N = 6).
Despite NO synthesis inhibition, standard PD solutions reversed these
hemodynamic effects with both 1.5% and 4.25% Dianeal (Baxter) rapidly
reversing the vasoconstriction and restoring blood flow back to baseline
values. When Dianeal and L-NAME were simultaneously superfused, no
L-NAME induced vasoconstriction occurred and Dianeal maintained
vasodilatory properties despite L-NAME (P < 0.01, N = 5). This
investigation reaffirms that basal levels of NO are important in maintain-
ing normal hemodynamics in the mesenteric microcirculation. Reversal of
the L-NAME induced arteriolar hemodynamic effects by Dianeal suggests
that the endogenous NO synthesis inhibitor ADMA has no significant
effects in the regulation of the mesenteric microvascular arteriolar hemo-
dynamics during PD. Since these PD solutions remain vasoactive despite
NO synthesis inhibition, this suggests that these PD solutions possess
vasoactive properties primarily through a NO independent mechanism.
Nitric oxide is increasingly recognized as an important bioregu-
latory molecule of the microcirculation affecting numerous fun-
damental microcirculatory processes. Inhibition of nitric oxide
synthesis results in significant renal and mesenteric arteriolar
vasoconstriction, increases in vivo microvascular permeability and
acts as a pro-inflammatory stimulus (as evidenced by a marked
increase in the number of adherent leukocytes in postcapillary
venules), [1—4]. Nitric oxide is synthesized from L-arginine by a
family of enzymes known as nitric oxide synthases (NOS), [5].
NOS is present in two major forms: a constitutive form and an
inducible form [6]. The constitutive form of NOS present in
endothelial cells may be inhibited by a variety of arginine analogs,
including the exogenous arginine derivative N°-nitro-L-arginine
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methyl ester (L-NAME) and the endogenous derivative N°
NGdimethylarginine (also known as asymmetrical dimethylargi-
nine, ADMA) [1, 2, 71. Recently, ADMA has been reported to be
present in elevated concentrations in chronic renal failure [8].
Patients with end-stage renal disease (ESRD) may have plasma
concentrations of ADMA in the 5 j.LM range, which is approxi-
mately eight fold greater than patients with normal renal function
[8—10]. This observation could be particularly significant for
patients with ESRD who are maintained on chronic peritoneal
dialysis since the accumulation of ADMA may have important
consequences in regulation of the mesenteric microvascular he-
modynamics during peritoneal dialysis.
Peritoneal dialysis solutions have been previously shown to
possess vasoactive properties in the mesenteric microcirculation
[11, 12]. Superfusion of a hypertonic peritoneal dialysis solution
on arterioles produces a transient vasoconstriction followed by a
sustained vasodilation. The vasoactive properties of these solu-
tions have been attributed to the solution's hyperosmolarity and
acetate or lactate buffers [13]. Recently, it has been demonstrated
that hyperosmolar sodium solutions perfused into intestinal
lymph produce vasodilation of submucosal intestinal arterioles
through a mechanism partly mediated by endothelium-derived
relaxing factor (nitric oxide), [14]. Whether or not hyperosmolar
peritoneal dialysis solutions produce arteriolar vasodilation
through a nitric oxide dependent mechanism, and how nitric oxide
inhibitors affect the vasoactive properties of peritoneal dialysis
solutions has been previously unknown. If hypertonic peritoneal
dialysis solutions produce vasodilation through a nitric oxide
dependent mechanism then elevated concentrations of endoge-
nous inhibitors of nitric oxide synthesis as seen in ESRD poten-
tially could alter the vasoactive properties of standard peritoneal
dialysis solutions. In order to investigate these possibilities in vivo
hemodynamic studies of mesenteric arterioles were performed
using a standard peritoneal dialysis solution (Dianeal; Baxter
Health Care Corporation, Deerfield, IL, USA) during conditions
of nitric oxide synthesis inhibition.
Methods
Male Sprague-Dawley rats (125 to 350 g) were anesthetized
with mactin (thiobutabarbital sodium) 120 mg/kg intraperitone-
ally. A tracheotomy was performed to maintain a patent airway
and the right carotid artery was canulated for blood pressure
measurement. The rat was placed in the supine position on a
plexiglass microscopic stage and a midline abdominal incision was
made. A segment of the small bowel was exposed through the
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midline incision and the mesentery was prepared for in vivo
microscopic observation. The mesentely was draped over a glass
cover slip approximately 2 cm2 and the exposed bowel was
covered with moist gauze to prevent tissue dehydration 15]. The
rat was maintained at physiologic temperature using a warming
lamp. A mesenteric arteriole (20 to 35 xm) was identified for
study using an inverted microscope (Fluovert FS, Leitz, Germa-
ny). The mesentery was continuously superfused with a nonvaso-
active peritoneal dialysis solution (NVAPD) at 3 mi/mm followed
by the appropriate experimental solution as outlined in the
experimental protocols below. The composition of the NVAPD
solution was sodium 140 mEq/liter, calcium 3.5 mEq/liter, potas-
sium 3 mEq/liter, magnesium 2.5 mEq/liter, chloride 126 mEq/
liter, bicarbonate 20 mEq/Iiter, sulfate 2.5 mEq/liter and dextrose
120 mg/dl (modified from [16]). The composition of 1.5% Dianeal
was sodium 132 mEq/liter, calcium 3.5 mEq/liter, magnesium 0.5
mEq/liter, chloride 96 mEq/liter, lactate 40 mEq/liter and dex-
trose 1500 mg/dl, with a calculated osmolality of 346 mOsm/liter.
The composition of 4.25% Dianeal was sodium 132 mEq/liter,
calcium 3.5 mEq/liter, magnesium 0.5 mEq/liter, chloride 96
mEq/liter, lactate 40 mEq/liter and dextrose 4250 mg/dl, with a
calculated osmolality of 485 mOsm/liter. The experimental solu-
tions were bubbled with a mixture of 5%C02 and 95%N2 prior to
superfusion.
A video camera (Dage-MTI CCD, C72, Michigan City, IN,
USA) mounted on the microscope projected the image onto a
video monitor (SONY1943MD, SONY, Tokyo, Japan) and the
images were recorded with a videocassette recorder (SONY
9500MD). A video time-date generator (Panasonic WJ-810, Ja-
pan) projected the time, date and stopwatch function onto the
monitor. The blood pressure was monitored with a pressure
transducer (1050 BPR, Biopac Systems Inc., Goleta, CA, USA)
connected to a DA 100 amplifier (Biopac Systems Inc.) and an
analog to digital converter (MP100, Biopac Systems Inc.). The
temperature was monitored with a temperature probe (TSD
102A, Biopac Systems Inc.) connected to a SKT100 amplifier
(Biopac Systems Inc.) and an analog to digital converter MP100.
Arteriole microvascular diameter was measured on line using a
videocaliper (Microcirculation Research Institute, Texas A&M
University, College Station, TX, USA). Center line red blood cell
velocity (VRBC) was measured using an optical Doppler veloci-
meter (Microcirculation Research Institute). Both the videocali-
per and the velocimeter were connected to a Universal Interface
Module UIM 100 (Biopac Systems Inc.) and an MPIOO analog to
digital converter. Arteriole diameter, VRBC, blood pressure and
temperature were continuously monitored with the information
downloaded to a Macintosh Quadra 650 computer (Apple) using
the Acknowledge 3.0 program (Biopac Systems Inc.). The video-
caliper was calibrated using a slide objective micrometer and the
doppler velocimeter was calibrated using a rotating disk coated
with red blood cells.
Experimental protocols
Single, unbranched mesenteric arterioles (20 to 35 xm) were
identified for study. The study consisted of five experimental
protocols: a Control Group and Experimental Groups 1 to 4.
Figure 1 outlines the different solution time periods and illustrates
the transition between experimental solutions in each group. All
experimental solutions were warmed to 37°C prior to mesenteric
superfusion and superfused at 3 ml/min.
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Fig. 1. An experimental time line for the superfused solutions for each
Experimental Group. Abbreviations are: B, baseline period; NVAPD,
nonvasoactive peritoneal dialysis solution. Symbols are: (LI) NVAPD; (hI)
NVAPD + L-NAME; () NVAPD + ADMA; (U) 4.25% Dianeal; (U)
1.5% Dianeal; () 4.25 Dianeal + L-NAME.
Control Group. The stability of the experimental preparation
over time was tested by superfusing the mesenteiy with the
NVAPD control solution. As in each experimental group, arte-
riole vessel diameter, center line red blood cell velocity (VRBC)
and blood pressure were continuously monitored and recorded.
This information was then available for future data analysis.
Experimental Groups 1, 2 and 3. The objective of these Exper-
imental Groups was to determine the arteriole hemodynamic
effects of the inhibitors of nitric oxide synthesis, L-NAME and
ADMA, and to examine the hemodynamic effects of standard
hyperosmolar peritoneal dialysis solutions (1.5% or 4.25% Dia-
neal) following nitric oxide synthesis inhibition. The mesentery
was superfused for 40 minutes with NVAPD solution (30-mm
stabilization period followed by a 10-mm baseline period). Fol-
lowing the baseline period, 100 fLM L-NAME or ADMA was
added to the NVAPD solution and superfused for 60 minutes.
The superfused solution was then changed to 4.25% Dianeal for
Experimental Groups 1 and 2 or 1.5% Dianeal for Experimental
Group 3 and superfused for 20 minutes.
Experimental Group 4. The objective of Experimental Group 4
was to determine the arteriole hemodynamic effects of simulta-
neous superfusion of L-NAME and 4.25% Dianeal. The mesen-
tety was superfused for 40 minutes with NVAPD solution (30-mm
stabilization period followed by a 10-mm baseline period). Fol-
lowing the baseline period, 4.25% Dianeal was superfused for 20
minutes. Then 100 IxM L-NAME was added to the 4.25% Dianeal
solution and superfused for 60 minutes. The superfused solution
was then changed back to 4.25% Dianeal for 20 minutes.
Statistical analysis
All values for each 10-minute time period were expressed as
means SCM. The data were analyzed using an analysis of
variance with Tukey's post-hoc test. Statistical significance was set
at P < 0.05.
Results
In the Control Group there were no significant differences in
mean values for arteriole diameter or VRBC in any 10 minute time
Expgroup4
Expgroup3
Exp group 2
Exp group 1
Control group
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Table 1. Summary of mean arteriole hemodynamic data
Solution
Time miii
NVAPD
Baseline 0 to 10 10 to 20 20 to 30 30 to 40 40 to 50 50 to 60 60 to 70 70 to 80 80 to 90 90 to 100
Control Group
NVAPD
Diameter un 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.6 0.7 25.4 0.7 25.5 0.9
RBC Velocity 7.9 1.3 8.0 1.4 8.1 1.3 9.2 1.4 9.4 1.5 9.3 1.5 9.6 1.6 10.4 1.4 8.3 2.0 8.4 2.3 8.7 1.6
mm/sec
Solution
Time miii
NVAPD
Baseline
NVAPD + 100 JLM L-NAME or ADMA 4.25 or 1.5% Dianeal
50 to 60 60 to 70 70 to 800 to 10 10 to 20 20 to 30 30 to 40 40 to 50
Experimental Group I
L-NAME, 4.25%
Dianeal
Diameter pn 28.0 2.8 25.0 2.7 24.8 3.6 22.8 4.1 21.2 4.6 20.2 3.7 22.2 4.1 29.2 5.1 31.6 3.8
RBC Velocity 8.2 7.1 1.6 5.2 1.7 4.6 1.6 3.9 1.6 3.8 1.6 3.6 1.5 8.1 2.0 8.3 1.6
mm/sec
Experimental Group 2
ADMA, 4.25%
Dianeal
Diameter p.m 30.1 2.0 30.1 2.0 28.3 1.7 26.5 1.8 23.3 2.2 21.5 2.5 20.5 2.5 30.0 2.4 32.5 2.5
RBC Velocity 9.8 0.9 8.7 0.6 7.2 0.4 8.4 0.7 6.4 0.6 5.7 0.7 5.1 1.1 8.9 1.1 9.6 0.9
mm/sec
Experimental Group 3
L-NAME, 1.5%
Dianeal
Diameter p.m 25.8 0.7 25.4 0.5 24.8 0.7 23.4 0.5 21.4 1.4 20.4 1.8 17.6 1.7 23.4 0.7 27.0 0.7
RBC Velocity 8.9 0.7 8.1 0.7 7.2 1.2 6.4 1.3 5.7 1.2 4.2 0.8 3.9 0.5 7.9 1.2 8.1 1.4
mm/sec
.Solution
Time mm
NVAPD
Baseline
4.25% Dianeal 4.25% Dianeal + 100 JiM L-NAME 4.25% Dianea!
0 to 10 10 to 20 20 to 30 30 to 40 40 to 50 50 to 60 60 to 70 70 to 80 80 to 90 90 to 100
Experimental Group 4
L-NAME in 4.25%
Dianeal
Diameter un 28.0 2.5 30.6 2.8 32.6 3.2 32.2 3.3 31.8 3.2 32.2 3.1 31.4 3.4 31.8 3.2 31.0 3.3 31.6 3.0 31.6 3.2
RBC velocity 8.9 1.2 9.7 1.7 10.9 1.5 10.3 1.5 9.8 1.3 8.4 1.7 7.4 1.9 7.6 1.9 6.9 2.1 7.4 1.7 8.1 1.6
mm/sec
Abbreviation is: NVAPD, nonvasoactive peritoneal dialysis solution. Values are means SEM.
period. This demonstrates the stability of the experimental prep-
aration over time. In Experimental Group 1, when compared to
the baseline period, 100 /.LM L-NAME produced significant arte-
riolar vasoconstriction (maximum vasoconstriction occurring in
the 40 to 50 mm time interval: 20.0 3.7 vs. 28.0 2.8 .tm, P =
0.01, N = 5) and decreased VRBC (maximum decline in VRBC
occurring in the 50 to 60 mm time interval: 3.6 1.5 vs. 8.2 2.2
mm/second, P < 0.05, N = 5). 4.25% Dianeal reversed the
L-NAME induced vasoconstriction (31.6 3.8 vs. 20.0 3.7 jim,
P < 0.01, N = 5) and restored VRBC (8.3 1.6 vs. 3.6 1.5
mm/second, P < 0.05, N = 5). In Experimental Group 2, when
compared to the baseline period, 100 JiM ADMA produced
significant arteriolar vasoconstriction (maximum vasoconstriction
occurring in the 50 to 60 mm time interval: 20.5 2.5 vs. 30.1
2.0 jim, P < 0.01, N = 6) and decreased VRBC (maximum decline
in VRBC occurring in the 50 to 60 mm time interval: 5.1 1.1 vs.
9.8 0.9 mm/see, P < 0.01, N = 6). The 4.25% Dianeal reversed
the ADMA induced vasoconstriction (32.5 2,5 vs. 20.5 2.5
jim,P < 0.001, N = 6) and restored VRBC (9.6 0.9 vs. 5.1 1.1
mm/second, P 0.01, N = 6). In Experimental Group 3, when
compared to the baseline period, 100 JiM L-NAME produced
significant arteriolar vasoconstriction (maximum vasoconstriction
occurring in the 50 to 60 mm time interval: 17.6 1.7 vs. 25.8
0.7 p.m,P < 0.01, N = 5) and decreased VRBC (maximum decline
in VRBC occurring in the 50 to 60 mm time interval: 3.9 0.5 vs.
8.9 0.7 mm/second, P < 0.01, N = 5). The 1.5% Dianeal
reversed the L-NAME induced vasoconstriction (27.0 0.7 vs.
17.6 1.7 jim,P < 0.01, N 5) and restored VRBC (8.1 1.4 vs.
3.9 0.5 mm/second, P < 0.01, N = 5). Table 1 gives the mean
hemodynamic data for the Control and Experimental Groups 1
through 4. The data for arteriole diameter and VRBc for Exper-
imental Groups 1 to 3 are graphically illustrated in Figures 2 to 4,
respectively. Figure 5 shows a comparison in the percent change
in the arteriole diameter for Experimental Groups 1 to 3, and
Figure 6 shows a comparison in the percent change in the VRBC
for Experimental Groups ito 3. These data also demonstrate that
the significant changes in arteriole diameter and VRBC secondary
to basal nitric oxide production inhibition occur primarily in the
second 30-minute period of the 60-minute L-NAME or ADMA
superfusion period. In addition, further studies demonstrated that
L-NAME induced vasoconstriction was reversed with pH adjusted
4.25% Dianeal (pH = 7.38, P < 0.01, N = 4). This is in agreement
with Miller et al, who found it unlikely that low pH accounted for
the vasoactive properties of peritoneal dialysis solutions since
adjustment of pH to 7.0 to 7.4 did not alter vasodilator responses
in the rat cremaster muscle [11].
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decline in VRBC (50 to 60 mm), N = 5.
10) as compared to ADMA (100 jxM) to 68% of baseline diameter
Combining the data for each time period in L-NAME from (20.5 2.5 vs. 30.1 2.0 m, P < 0.01, N = 6). In addition,
Experimental Groups 1 and 3 demonstrates that L-NAME (100 L-NAME decreases VRBC to 44% of baseline velocity (3.8 0.8
I.LM) produces maximum arteriolar vasoconstriction to 74% of vs. 8.5 1.1 mm/second, P < 0.001, N = 10) while ADMA
baseline diameter (19.9 2.2 vs. 26.9 1.4 xm, P < 0.001, N = decreases VRBC to 52% of baseline (5.1 1.1 vs. 9.8 0.9
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mm/second, P < 0.01, N = 6). Figure 7 is a photomicrograph of In Experimental Group 4 the arteriole hemodynamic effects of
an intravital microscopic image of an arteriole during an experi- simultaneous superfusion of L-NAME and 4.25% Dianeal were
ment with ADMA and Dianeal. examined. As expected, the initial Dianeal period produced
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B C
Fig. 7. Photomicrograph of an intravital microscopic image of an arteriole during an experiment with ADMA. A. The baseline diameter (33 jsm). B. ADMA
induced vasoconstriction (16 jLm). C. The reversal of the ADMA induced vasoconstriction by 4.25% Dianeal (38 /.Lm). The dotted white lines in A
represent the video caliper, and the two black dots in the vessel represent the optically placed doppler velocimeter. Magnification 200x.
vasodilation when compared to the baseline period (32.6 3.2 vs.
28.0 2.5 p.m, P < 0.01, N = 5). Despite the addition of 100 j.m
L-NAME to the 4.25% Dianeal, no vasoconstriction occurred in
any time period during which the nitric oxide synthesis inhibitor
was present. Furthermore, when compared to the baseline period,
the vessel remained vasodilated for all time periods during which
L-NAME was simultaneously superfused with the Dianeal (P
0.01 and P 0.05; Fig. 8; N = 5). Following the L-NAME plus
Dianeal period, Dianeal was again superfused but no additional
vasodilation occurred. There was no significant difference in
arteriole diameter for the initial Dianeal period versus L-NAME
plus Dianeal period versus the final Dianeal period. In regard to
the VRBC, there was no significant difference in the L-NAME plus
Dianeal period versus the baseline period or the final Dianeal
period. One point of significant difference did occur in the 70- to
80-minute superfusion time period (which corresponds to the last
10 mm of the L-NAME in Dianeal period) as compared to the 10-
to 20-minute time period (which corresponds to the last 10 mm
period of the initial Dianeal period; P < 0.05). Thus, 4.25%
Dianeal completely prevented the L-NAME induced vasocon-
striction and the L-NAME induced decrease in V1 with the
exception of one 10-minute time period. The transient arteriolar
vasoconstrictive effects of peritoneal dialysis solutions previously
described by Miller et al in small arterioles (baseline diameter
approximately 8 to 10 jxm, [11]) was an inconsistent finding in
arterioles with a baseline diameter 20 to 35 (occurring in only
2 of 5 arterioles in Experimental Group 4). Finally, there were no
significant differences in blood pressure in any Experimental
Group when comparing the baseline period to two 30-minute
inhibitor time periods and the Dianeal periods.
Discussion
This study confirms previous observations that basal levels of
nitric oxide are important in maintaining normal arteriolar vas-
cular tone and blood flow in the mesenteric microcirculation [1,
2]. Both the exogenous inhibitor, L-NAME, and the endogenous
inhibitor, ADMA, produce marked arteriolar vasoconstriction
and diminished blood flow. L-NAME results in maximum vaso-
constriction to 74% of baseline diameter (combining the results
from the L-NAME induced vasoconstriction in Experimental
Groups 1 and 3), and ADMA results in maximal vasoconstriction
to 68% of baseline diameter. Both inhibitors decrease blood flow
as shown by a decrement in VRBC to 44% of baseline for
L-NAME and 52% of baseline VRBC for ADMA. These effects
are time dependent with the maximal effects occurring in the last
20 minutes of the 60-minute inhibitor period. Since basal levels of
nitric oxide production are critical in maintaining normal arterio-
lar microvascular hemodynamics, elevations of plasma levels of
endogenous nitric oxide synthesis inhibitors, such as what occurs
in renal failure, potentially could alter the microvascular hemo-
dynamics during peritoneal dialysis.
Despite the marked arteriolar hemodynamic changes which
occur with inhibition of nitric oxide production, standard perito-
neal dialysis solutions such as 1.5% and 4.25% Dianeal reverse
these microvascular effects. Both the 1.5% and 4.25% Dianeal
solutions rapidly (usually within the first 5 mm of exposure to
Dianeal) reverse the vasoconstriction and diminished blood flow
produced by nitric oxide synthesis inhibition. Both solutions
restore the arteriole diameter and blood flow back to baseline
values. Since these peritoneal dialysis solutions remain vasoactive
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These observations, however, do not negate the possibility that
hyperosmolar solutions produce nitric oxide dependent vasodila-
tion. Previous studies of intestinal submucosal arterioles have
demonstrated that increasing the osmolarity of the submucosal
interstitial space with hypertonic saline or mannitol produced a
dose-dependent arteriole vasodilation [141. This hyperosmolar
induced vasodilation was attenuated when endothelial derived
relaxing factor (nitric oxide) synthesis was inhibited by L-NAME.
Interestingly, the authors note that L-NAME attenuated 400
mOsm saline-induced vasodilation by approximately 50% but
equilmolar L-NAME attenuated 400 mOsm mannitol-induced
vasodilation by only 22%. These data suggest that the composition
of the hyperosmolar solution is important in determining the
amount of nitric oxide induced vasodilation. Furthermore, these
hyperosmolar solutions still produced vasodilation over baseline
- N 4.25% Dianeal values despite nitric oxide production inhibition. Therefore, for
a) C C C C C C C C C C hyperosmolar solutions at least two vasodilatory mechanisms areE E E E E E in effect, one being nitric oxide independent and the other nitric
oxide dependent. The degree of nitric oxide induced arteriole
vasodilation appears to be related to the composition of the
0) hyperosmolar solution.
Time period To further investigate the possibility that peritoneal dialysis
solutions could have a partial component of nitric oxide depen-
dent vasodilation, a group of experiments (Experimental Group
4) were performed in which the arteriole was first exposed to the
peritoneal dialysis solution followed by simultaneous superfusion
of the nitric oxide synthesis inhibitor and the peritoneal dialysis
solution. If these peritoneal dialysis solutions produce significant
vasodilation partially through a nitric oxide dependent mecha-
nism, then there should occur some relative vasoconstriction when
comparing the initial Dianeal period with the L-NAME plus
Dianeal period. The initial exposure of Dianeal produced the
expected vasodilation over baseline diameters. However, when
the Dianeal and L-NAME were simultaneously superfused, the
arteriole remained significantly vasodilated above the baseline
diameter throughout the entire L-NAME plus Dianeal period. In
addition, there was no significant difference in arteriole diameter
between the initial Dianeal period and the L-NAME plus Dianeal
period. Thus Dianeal appears to be vasoactive primarily through
a nitric oxide independent mechanism.
I 100J.IML-NAME I . .ADMA, methylguanidine and aminoguanidine are endogenous
NJ 4.5% panal guanidino compounds which accumulate in renal failure and
a) C C C C C C C C C C inhibit nitric oxide production [18]. ADMA appears to be theE E E E E E E E E E most potent endogenous inhibitor, with methylguanidine a weak
inhibitor, and aminoguanidine inhibiting only the inducible form
of nitric oxide synthase. ADMA is reported to accumulate in renal
failure to plasma concentrations of approximately 5 xM [8, 9]. In
Time period addition, it has also been suggested that local concentrations of
ADMA may be greater than the observed plasma concentrations
occurring in renal failure [2, 17—181. In this investigation the
experimental concentrations of the nitric oxide synthesis inhibi-
tors ADMA and L-NAME are approximately twenty times
greater than the increased plasma concentrations of ADMA
present in ESRD patients. Therefore, if the peritoneal dialysis
solutions attenuate and reverse the arteriolar hemodynamic ef-
fects of ADMA at the present experimental concentrations (100
Fig. 8. Hemodynamic data for Experimental Group 4. A. Arteriole diam-
eter. 4.25% Dianeal (initial period), 4.25% Dianeal plus L-NAME and
4.25% Dianeal (final period) all produced vasodilation when compared to
the baseline period, #P  0.05 and * 0.01. B. Red blood cell velocity
(VRBC). No significant change in VRBC in any time period except in the
final ten minutes of Dianeal plus L-NAME period (70 to 80 mm) when
compared to the last ten minute period of the initial Dianeal period (10 to
20 mm), P < 0.05, N = 5.
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(LM), then these dialysis solutions would be expected to overcome
any mesenteric arteriolar hemodynamic effects of ADMA ob-
served in ESRD.
Finally, it is well established that nitric oxide inhibition pro-
duces an inflammatoiy reaction in postcapillary venules, as evi-
denced by increased leukocyte adhesion to the venular endothe-
hum and leukocyte migration into the interstitial tissue [4]. In this
investigation no increases in leukocyte endothelial adhesive inter-
actions were observed in the arterioles with nitric oxide inhibition.
This is consistent with previous observations that the inflamma-
tory reaction in the mesenteric microcirculation, as evidenced by
alterations in leukocyte kinetics, is primarily confined to the
postcapillary venule [4, 19—20].
In summary, this study confirms that basal levels of nitric oxide
are important in maintaining normal vascular tone and blood flow
in the mesenteric microcirculation. Superfusion of the nitric oxide
synthesis inhibitors ADMA and L-NAME produces significant
vasoconstriction and diminishes blood flow in mesenteric arte-
rioles. The arteriolar hemodynamic effects of nitric oxide synthesis
inhibitors are reversed by a standard hypertonic peritoneal dial-
ysis solution (Dianeal). The vasoconstrictive effects of L-NAME
are completely prevented when arterioles are simultaneously
superfused with 4.25% Dianeal and L-NAME. This suggests that
this hypertonic peritoneal dialysis solution produces vasodilation
primarily independent of nitric oxide mediated mechanisms.
Finally, reversal of the arteriolar hemodynamic effects of nitric
oxide inhibition by Dianeal suggests that the endogenous inhibitor
of nitric oxide production, ADMA, has no significant effects in the
regulation of the mesenteric microvascular arteriolar hemody-
namics during peritoneal dialysis.
Reprint requests to Randall White, M.D., Division of Nephrology and
Hypertension, Department of Medicine, Louisiana State University Medical
Center, 1501 Kings Highway, P.O. Box 33932, Shreveport, Louisiana 71130-
3932, USA.
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